FunctionReceptor for hepatocyte growth factor and scatter factor. Has a tyrosine-protein kinase activity. Functions in cell proliferation, scattering, morphogenesis and survival.
Involvement in diseaseNote=Activation of MET after rearrangement with the TPR gene produces an oncogenic protein. Note=Defects in MET may be associated with gastric cancer. Defects in MET are a cause of hepatocellular carcinoma (HCC) [MIM:114550]. Defects in MET are a cause of renal cell carcinoma papillary (RCCP) [MIM:605074]. It is a subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into common renal cell carcinoma (clear cell, non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma. Note=A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes. Note=MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies.
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. Contains 3 IPT/TIG domains. Contains 1 protein kinase domain. Contains 1 Sema domain.
DomainThe kinase domain is involved in SPSB1 binding.
Post-translational modificationsDephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365.
MET proto oncogene, receptor tyrosine kinase antibody
Met proto-oncogene (hepatocyte growth factor receptor) antibody
Met proto-oncogene antibody
Met protooncogene antibody
Oncogene MET antibody
Proto-oncogene c-Met antibody
Scatter factor receptor antibody
SF receptor antibody
Tyrosine-protein kinase Met antibody
Anti-Met (c-Met) antibody images
Immunocytochemistry/ Immunofluorescence - Met (c-Met) antibody (ab63347)
ab63347, at 1/500 dilution, staining Met (c-Met) in A549 cells by Immunofluorescence, in the absence (left image) or presence (right image) of the immunising peptide.
Western blot - Met (c-Met) antibody (ab63347)
All lanes : Anti-Met (c-Met) antibody (ab63347) at 1/500 dilution
Lane 1 : HepG2 cell extracts Lane 2 : HepG2 cell extracts with immunising peptide at 10 µg
Lysates/proteins at 30 µg per lane.
Predicted band size : 156 kDa Observed band size : 156 kDa Additional bands at : 90 kDa. We are unsure as to the identity of these extra bands.
References for Anti-Met (c-Met) antibody (ab63347)
This product has been referenced in:
Vogel S et al. Activated platelets interfere with recruitment of mesenchymal stem cells to apoptotic cardiac cells via high mobility group box 1/Toll-like receptor 4-mediated down-regulation of hepatocyte growth factor receptor MET. J Biol Chem289:11068-82 (2014).
Read more (PubMed: 24567328) »